No connection

Search Results

LIVN

NEUTRAL
$62.78 Live
LivaNova PLC · NASDAQ
Target $79.64 (+26.8%)
$34.0 52W Range $71.92
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 13, 2026
Market cap
$3.43B
P/E
N/A
ROE
-19.2%
Profit margin
-17.5%
Debt/Equity
0.36
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
70%
LIVN presents a stark contrast between poor deterministic health and strong market momentum. The Piotroski F-Score of 2/9 indicates significant fundamental weakness, and the technical trend is currently bearish. However, the company maintains strong gross margins (68.01%) and a low debt-to-equity ratio (0.36), while analysts remain bullish with a target price of $79.64. The valuation appears attractive on a PEG basis (0.72), but the negative net profit margin and ROE suggest operational inefficiencies or significant non-operating losses.

Key Strengths

Strong Gross Margin of 68.01% indicating high product value
Low Debt/Equity ratio (0.36) suggesting a conservative capital structure
Consistent double-digit revenue growth (12.10% YoY)
Attractive PEG ratio of 0.72 suggesting undervaluation relative to growth
Strong analyst consensus with a target price (~$79.64) well above current price

Key Risks

Very weak Piotroski F-Score (2/9) signaling deteriorating fundamental health
Negative Profit Margin (-17.47%) and ROE (-19.24%)
Severe volatility in earnings, including a massive surprise miss in May 2025
Bearish insider sentiment and lack of insider buying
Significant disconnect between operating margin (12.97%) and net profit margin
AI Fair Value Estimate
Based on comprehensive analysis
$74.5
+18.7% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
40
Moderate
Value
70
Future
60
Past
50
Health
20
Dividend
0
AI Verdict
Speculative Hold
Key drivers: Low PEG ratio, Strong revenue growth, Poor Piotroski health score, Negative net profitability
Confidence
75%
Value
70/100

Ref P/E, PEG, Graham Number

Positives
  • Forward P/E of 13.71 is modest
  • PEG ratio of 0.72 is highly attractive
Watchpoints
  • Price/Book of 2.86 is slightly elevated for a company with negative ROE
Future
60/100

Ref Growth rates

Positives
  • Steady 12% revenue growth
  • Strong analyst target price
Watchpoints
  • Earnings growth is sharply negative (-45.60% YoY)
Past
50/100

Ref Historical trends

Positives
  • Impressive 1-year return of +83.9%
Watchpoints
  • Poor 5-year performance (-22.5%)
  • Erratic quarterly earnings track record
Health
20/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • Low Debt/Equity (0.36)
  • Current ratio above 1.0
Watchpoints
  • Piotroski F-Score of 2/9 is a critical weakness
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$62.78
Analyst Target
$79.64
Upside/Downside
+26.8%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for LIVN and closest competitors.

Updated 2026-04-10
LIV
LivaNova PLC
Primary
5Y
-22.5%
3Y
+45.9%
1Y
+83.9%
6M
+23.9%
1M
+0.8%
1W
-1.6%
BLL
BillionToOne, Inc.
Peer
5Y
-32.0%
3Y
-32.0%
1Y
-32.0%
6M
-32.0%
1M
+2.8%
1W
+6.2%
LEG
Legend Biotech Corporation
Peer
5Y
-34.7%
3Y
-64.1%
1Y
-41.9%
6M
-42.7%
1M
-10.4%
1W
-5.1%
ACA
ACADIA Pharmaceuticals Inc.
Peer
5Y
-31.3%
3Y
+1.1%
1Y
+22.8%
6M
-12.7%
1M
-8.3%
1W
-7.0%
KNS
Kiniksa Pharmaceuticals International, plc
Peer
5Y
+191.5%
3Y
+337.6%
1Y
+152.4%
6M
+24.2%
1M
+1.7%
1W
-3.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
13.71
PEG Ratio
0.72
P/B Ratio
2.86
P/S Ratio
2.47
EV/Revenue
2.33
EV/EBITDA
12.54
Market Cap
$3.43B

Profitability

Profit margins and return metrics

Profit Margin -17.47%
Operating Margin 12.97%
Gross Margin 68.01%
ROE -19.24%
ROA 5.17%

Growth

Revenue and earnings growth rates

Revenue Growth +12.1%
Earnings Growth -45.6%
Q/Q Revenue Growth +12.15%
Q/Q Earnings Growth -44.7%

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.36
Low debt
Current Ratio
1.36
Good
Quick Ratio
1.05
Good
Cash/Share
$11.62

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.4B
Gross Margin
66.4%
Op. Margin
11.8%
Net Margin
8.6%
Total Assets
$2.6B
Liabilities
$1.4B
Equity
$1.2B
Debt/Equity
1.17x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
61%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-06
$N/A
2026-02-25
$0.86
+5.6% surprise
2025-11-05
$1.11
+20.4% surprise
2025-08-06
$1.05
+20.3% surprise

Healthcare Sector Comparison

Comparing LIVN against 291 companies in the Healthcare sector (20 bullish, 99 neutral, 172 bearish)
Return on Equity (ROE)
-19.24%
This Stock
vs
-49.88%
Sector Avg
-61.4% (Below Avg)
Profit Margin
-17.47%
This Stock
vs
-9.43%
Sector Avg
+85.2% (Superior)
Debt to Equity
0.36
This Stock
vs
3.74
Sector Avg
-90.3% (Less Debt)
Revenue Growth
12.1%
This Stock
vs
80.78%
Sector Avg
-85.0% (Slower)
Current Ratio
1.36
This Stock
vs
3.72
Sector Avg
-63.4% (Weaker)

Similar Companies

Peer comparison within the same industry

LIVN LivaNova PLC
NEUTRAL
Mkt Cap
$3.4B
P/E
-
ROE
-19.2%
Price
$62.78
BLLN BillionToOne, Inc.
BEARISH
Mkt Cap
$3.4B
P/E
569.8
ROE
2.3%
Price
$74.08
 Compare with LIVN
LEGN Legend Biotech...
BEARISH
Mkt Cap
$3.4B
P/E
-
ROE
-29.1%
Price
$18.16
 Compare with LIVN
ACAD ACADIA...
NEUTRAL
Mkt Cap
$3.5B
P/E
9.0
ROE
39.9%
Price
$20.61
 Compare with LIVN
KNSA Kiniksa...
NEUTRAL
Mkt Cap
$3.6B
P/E
62.8
ROE
11.7%
Price
$47.08
 Compare with LIVN

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

MAKATSARIA VLADIMIR A.
Chief Executive Officer
Stock Award
2026-03-30
21,042 shares
BOLTON STEPHANIE
Officer
Stock Award
2026-03-30
17,815 shares
TEZEL AHMET
Officer
Stock Award
2026-03-30
3,408 shares
POLETTI FRANCO
Officer
Stock Award
2026-03-30
3,184 shares
KOZMINA NATALIA
Officer
Stock Award
2026-03-30
6,389 shares
SHVARTSBURG ALEX
Chief Financial Officer
Stock Award
2026-03-30
30,835 shares
POLETTI FRANCO
Officer
Option Exercise
2026-03-11
2,140 shares · $123,264
POLETTI FRANCO
Officer
Stock Award
2025-12-15
967 shares
HUTCHINSON MICHAEL DAMON
Officer
Stock Award
2025-12-15
2,254 shares
PODLOGAR SUSAN M
Director
Stock Award
2025-12-15
2,355 shares
STORY BROOKE
Director
Sell
2025-11-18
250 shares · $13,485
Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
11 analysts
Barclays
2026-02-27
Maintains
Equal-Weight Equal-Weight
Needham
2026-02-25
Maintains
Buy Buy
Barclays
2026-01-09
Maintains
Equal-Weight Equal-Weight
Stifel
2026-01-07
Maintains
Buy Buy
Keybanc
2025-12-19
init
Overweight
Mizuho
2025-12-17
Maintains
Outperform Outperform
Mizuho
2025-11-13
Maintains
Outperform Outperform
Baird
2025-11-13
Maintains
Outperform Outperform
Baird
2025-11-06
Maintains
Outperform Outperform

Past News Coverage

Recent headlines mentioning LIVN from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile